DiaMedica Therapeutics Inc (DMAC)vsBeiGene, Ltd. (ONC)

DMAC

DiaMedica Therapeutics Inc

NASDAQ

$6.89

-5.49%

HEALTHCARE · Cap: $352.04M

ONC

BeiGene, Ltd.

NASDAQ

$283.45

+2.81%

HEALTHCARE · Cap: $31.62B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).

DMAC

Avoid

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0

ONC

Hold

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5

Piotroski: 5/9Altman Z: 0.26

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DMAC.

ONCSignificantly Overvalued (-1983.5%)

Margin of Safety

-1983.5%

Fair Value

$16.86

Current Price

$283.45

$266.59 premium

UndervaluedFair: $16.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DMAC0 strengths · Avg: 0/10

No standout strengths identified

ONC2 strengths · Avg: 9.5/10

Revenue GrowthGrowth

32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth

0.259/10

Conservative balance sheet, low leverage

Areas to Watch

DMAC4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$352.04M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

ONC4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Return on EquityProfitability

7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability

5.4%3/10

5.4% margin — thin

P/E RatioValuation

111.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DMAC

DMAC has a balanced fundamental profile.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bear Case : DMAC

The primary concerns for DMAC are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.

Key Dynamics to Monitor

DMAC profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.

DMAC carries more volatility with a beta of 1.10 — expect wider price swings.

ONC is growing revenue faster at 32.8% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (42/100 vs 20/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DiaMedica Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

DMAC vs VRTX DMAC vs REGN DMAC vs ARGX DMAC vs ALNY DMAC vs INSM ONC vs VRTX ONC vs REGN ONC vs ARGX ONC vs ALNY ONC vs INSM

Want to dig deeper into these stocks?

Full DMAC Analysis →Full ONC Analysis →